OLIVIER COLOMBAN
Université Claude Bernard Lyon 1, Mapi-Naxis (MAPI GROUP), Aix-Marseille Université
About
Cancer researcher with over 15 years of experience applying advanced mathematics and statistical modeling in oncology within the EA 3738 CICLY team (Centre for Innovation in Cancer of Lyon) at Lyon-Sud Medical School, Université Claude Bernard Lyon 1 (UCBL).
With dual Master’s degrees in Engineering Mathematics (DESS, 2005) and Biostatistics (DEA, 2006) from UCBL, I joined the team in 2008. My work integrates cutting-edge mathematical frameworks and computational techniques to solve complex biomedical challenges. I specialize in pharmacokinetic-pharmacodynamic (PK/PD) modeling, non-linear mixed effect models, and regression analyses, leveraging these tools to drive innovation in biomarker kinetics and oncology research.
Over the last decade, my primary focus has been on developing and refining mathematical models to describe the kinetics of serum tumor markers (CA-125, PSA, hCG, HE4, nucleosomes), enabling more precise biomarker analysis. Explore this work further at: https://www.biomarker-kinetics.org.
Currently, I lead the development of the KELIM methodology and manage IT operations for the research unit, ensuring seamless integration of computational tools with scientific inquiry.
Key Expertise:
- Advanced mathematical modeling in biomedical contexts;
- Statistical analysis and computational mathematics;
- Non-Linear Mixed Effect Modeling;
- Pharmacokinetics-Pharmacodynamics modeling & simulation;
- Biomarker kinetics and predictive modeling (CA-125, PSA, hCG, etc.);
- Regression models (linear, survival, logistic, etc.);
- Software proficiency: NONMEM, R, MONOLIX, SAS (stat/macro);
- IT management and infrastructure optimization;
- Operating systems: Windows, Windows Server 2019/2008, Mac.
Employment
-
Université Claude Bernard Lyon 1 Quantitative Modeling Engineer | Research2008 - Present
-
Mapi-Naxis (MAPI GROUP) Statisticien2007 - 2008
-
Université Claude Bernard Lyon 1 Chargé d'étude2006 - 2007
Education
-
Université Claude Bernard Lyon 1 DEA Modélisation en Épidémiologie & Recherche Clinique2005 - 2006
-
Université Claude Bernard Lyon 1 DESS Statistique, Informatique et Techniques Numériques2004 - 2005
-
Aix-Marseille Université 4 years university degrees in applied mathematics to economics2000 - 2004
Projects & Funding
Projects & funding information is unavailable.
Publications (54)
- Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial Save
- Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study Save
- Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets. Save
- Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA Save
- Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients Save
- Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting” Save
- KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer Save
- 792P Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis Save
- 793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO) Save
- Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis Save